Myasthenia Gravis Drug Gets FDA Nod Myasthenia Gravis Drug Gets FDA Nod

The monoclonal antibody rozanolixizumab (Rystiggo) is indicated to treat adults with the two most common subtypes of generalized myasthenia gravis.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Neurology & Neurosurgery News Alert Source Type: news